TOPIC: Cefazolin in Dextrose Injection USP, 2 g/100mL (20 mg /mL) Single-Dose Infusion Bag in 100 mL By Baxter: Recall - Due To Particulate Matter Found in Solution
AUDIENCE: Patient, Health Care Professional, Pharmacy, Cardiology
ISSUE: Baxter is recalling Lot LD175708, Exp 14-Feb 2027 of Cefazolin in Dextrose Injection due to a report of particulate matter found in the solution identified as cardboard.
Risk Statement: The use of the defective product has a reasonable probability of causing pulmonary emboli (blockage in pulmonary blood vessels), occlusions of other blood vessels (which can lead to tissue death and possible organ damage), and/or phlebitis (inflammation of the walls of veins, which may lead to clotting). Systemically, foreign particles infused intravenously can cause systemic activation of the immune system, organ dysfunction, and hemolysis (breakdown of blood cells).
To date, Baxter has not received any reports of adverse events related to this issue.
The impacted product was distributed from 3/25/2025 to 6/30/2025 in the United States.
For more information about this recall, click on the red button "Read Recall" below.
BACKGROUND: The product being recalled is used intravenously to treat bacterial infections or prevent them during surgery.
RECOMMENDATIONS:
-
Customers should immediately discontinue use of and return all affected units in accordance with their facility’s process. Baxter is contacting customers with instructions on how to identify and return the impacted product.
-
For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001.
|
